Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
In clash over science and national security, Chinese rival to Illumina struggles with US expansion
Last year
In Focus
Diagnostics
LianBio to shutter, ending Shanghai-based startup’s transatlantic ambitions
Last year
People
Startups
Seattle biotech founded by former Seagen leaders nabs $112M for three clinical-stage ADCs
Last year
Financing
Startups
Updated: ‘Ruthless’ pipeline prioritization, obesity and China: Three takeaways from AstraZeneca’s Q4
Last year
Pharma
House committee plans hearing on Chinese biotech competition as tensions mount
Last year
Pharma
I-Mab Biopharma to split US, China businesses to cut costs, mitigate potential risks
Last year
Deals
ArriVent outlines plans for $135M IPO in second biotech listing of 2024
Last year
Financing
Startups
AstraZeneca reshuffles China leadership, sets up biopharma group to mirror global structure
Last year
People
Pharma
BioNTech pays $20M upfront for two monoclonal antibodies from China's WuXi Biologics
Last year
Deals
CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic
Last year
Financing
Startups
RTW, Bayer back Cytokinetics-allied Ji Xing Pharmaceuticals with $162M: #JPM24
Last year
Financing
Pharma
GSK to buy asthma biotech Aiolos Bio for up to $1.4B three months after startup emerged: #JPM24
Last year
Deals
Pharma
Beijing oncology biotech Avistone raises $140M Series B for commercialization in China, expansion into US
Last year
Financing
Another day, another ADC: OnCusp secures $100M Series A from Novo, OrbiMed and others to run PhI trial
Last year
Financing
Startups
Exclusive: After Turning Point success, oncology vets in-license first asset for Avenzo Therapeutics
Last year
Startups
Deals
Trailing Novartis and Eli Lilly, radiopharmaceuticals startup Full-Life Technologies nabs $63M to test new PSMA drug
Last year
Financing
Manufacturing
Roche inks $50M ADC pact with Chinese biotech as field's flurry spills over into 2024
Last year
Deals
Pharma
AstraZeneca makes $1B deal for Gracell and its cell therapies, adding to China ties
Last year
Deals
Cell/Gene Tx
GSK secures another ex-China ADC deal with Hansoh Pharma with $185M upfront
Last year
Deals
Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug
Last year
Deals
Small transpacific team led by Lilly, Everest vet turns to computational tools for next wave of peptide drug discovery
Last year
Financing
Startups
BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance
Last year
Deals
FDA greenlights first made-in-China PD-1 as Junshi, Coherus beat BeiGene to the punch
Last year
FDA+
Danaher’s third-quarter revenue from biotech services down 19% amid slowdown in China, US
Last year
Outsourcing
Pharma
First page
Previous page
6
7
8
9
10
11
12
Next page
Last page